Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Cipher announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
Mississauga, Ontario - Cipher Pharmaceuticals announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Limited for Ranbaxy to market, sell and distribute CIP-ISOTRETINOIN in the United States, MarketWatch reports.
Mississauga, Ontario
- Cipher Pharmaceuticals announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Limited for Ranbaxy to market, sell and distribute CIP-ISOTRETINOIN in the United States, MarketWatch reports.
Under the terms of agreement, Cipher received an initial upfront milestone payment of $1 million. Pre-and post- commercialization milestone payments of up to $23 million are also part of the agreement.
Related Videos
Related Content
